These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35366166)

  • 61. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
    Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.
    Naderi-Azad S; Sullivan R
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263
    [No Abstract]   [Full Text] [Related]  

  • 64. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
    Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
    [No Abstract]   [Full Text] [Related]  

  • 65. First-line immunotherapy versus targeted therapy in patients with
    Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
    Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
    [No Abstract]   [Full Text] [Related]  

  • 66. Combination therapy of melanoma using kinase inhibitors.
    Heppt MV; Tietze JK; Graf SA; Berking C
    Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer.
    Ragusa F; Ferrari SM; Elia G; Paparo SR; Balestri E; Botrini C; Patrizio A; Mazzi V; Guglielmi G; Foddis R; Spinelli C; Ulisse S; Antonelli A; Fallahi P
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628540
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 69. AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
    Caputo E; Miceli R; Motti ML; Taté R; Fratangelo F; Botti G; Mozzillo N; Carriero MV; Cavalcanti E; Palmieri G; Ciliberto G; Pirozzi G; Ascierto PA
    J Transl Med; 2014 Jul; 12():216. PubMed ID: 25074438
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
    Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
    Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combinatorial Approaches to the Treatment of Advanced Melanoma.
    Munhoz RR; Postow MA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
    Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G
    J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS; Crandall H; Dahlman K; Kelley MC
    J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
    Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
    JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
    Queirolo P; Spagnolo F
    Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of Recurrent Melanoma Following Adjuvant Therapy.
    Malissen N; Grob JJ
    Am J Clin Dermatol; 2023 May; 24(3):333-341. PubMed ID: 36890427
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.
    Jung T; Haist M; Kuske M; Grabbe S; Bros M
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576054
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.